Adaptive Trial Simulatorv0.1.0

A pharmaceutical company is designing a Phase III trial for a new oncology drug. Using adaptive design, they set interim looks to assess efficacy and futility, and adjust sample size based on observed effect size. The simulator helps validate Type I error control and power, reducing the risk of trial failure and saving resources.

A biotech firm runs a multi-arm trial to select the optimal dose of a new biologic. Using the 'drop-the-loser' design, they simulate dropping inferior arms at interim analyses, focusing resources on promising doses. The simulator predicts power and expected sample size, enabling more efficient dose selection.

A university biostatistics department studies the properties of different alpha spending functions (O'Brien-Fleming vs. Pocock) under various scenarios. They use the simulator to compare Type I error inflation and power across spending functions, publishing results to inform regulatory guidance.

A medical device company conducts a post-market study to confirm safety and efficacy. Using the adaptive re-estimation design, they simulate sample size adjustments based on early data while preserving alpha. The simulator helps ensure the study meets regulatory requirements for post-market surveillance.

A CRO offers adaptive trial design simulation as a consulting service for sponsors. They use the tool to optimize interim analysis plans and sample size re-estimation strategies, providing clients with actionable insights on power, expected sample size, and early stopping probabilities. This enhances the value of their trial design services.

Offer the adaptive trial simulator as a cloud-based platform where users pay a subscription fee. This model allows ongoing revenue from pharmaceutical, biotech, and academic users who need flexible, on-demand simulation capabilities without local installation.

Provide expert consulting services to design and simulate adaptive trials for clients, using the tool as a core offering. Charge per project or package, including customization of simulation parameters and interpretation of results for regulatory submissions.

License the simulation engine to contract research organizations (CROs) or pharmaceutical companies for integration into their internal workflows. Offer one-time license fees plus maintenance/support contracts, enabling users to white-label the tool.